[go: up one dir, main page]

MX2010009753A - Composiciones que contienen apoaecuorina y metodos de uso de las mismas. - Google Patents

Composiciones que contienen apoaecuorina y metodos de uso de las mismas.

Info

Publication number
MX2010009753A
MX2010009753A MX2010009753A MX2010009753A MX2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A
Authority
MX
Mexico
Prior art keywords
methods
apoaequorin
same
quality
containing compositions
Prior art date
Application number
MX2010009753A
Other languages
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of MX2010009753A publication Critical patent/MX2010009753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan por la presente invención composiciones las cuales contienen apoaecuorina y métodos para uso en tratamiento de síntomas y trastornos relacionados a desequilibrios de calcio asociados con, por ejemplo, calidad del sueño, calidad de energía, calidad de humor, calidad de memoria o dolor.
MX2010009753A 2008-03-11 2009-03-11 Composiciones que contienen apoaecuorina y metodos de uso de las mismas. MX2010009753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3544308P 2008-03-11 2008-03-11
PCT/US2009/036767 WO2009114597A1 (en) 2008-03-11 2009-03-11 Apoaequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
MX2010009753A true MX2010009753A (es) 2010-09-30

Family

ID=40627496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009753A MX2010009753A (es) 2008-03-11 2009-03-11 Composiciones que contienen apoaecuorina y metodos de uso de las mismas.

Country Status (19)

Country Link
US (1) US8796213B2 (es)
EP (1) EP2262525B1 (es)
JP (1) JP5508294B2 (es)
KR (1) KR101643662B1 (es)
CN (2) CN101969979A (es)
AU (1) AU2009223010B2 (es)
BR (1) BRPI0909435A2 (es)
CA (1) CA2717322C (es)
CY (1) CY1114366T1 (es)
DK (1) DK2262525T3 (es)
ES (1) ES2401754T3 (es)
HR (1) HRP20130205T1 (es)
IL (1) IL207827A (es)
MX (1) MX2010009753A (es)
NZ (1) NZ588437A (es)
PL (1) PL2262525T3 (es)
PT (1) PT2262525E (es)
SI (1) SI2262525T1 (es)
WO (1) WO2009114597A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074798A1 (en) * 2011-11-15 2013-05-23 Quincy Bioscience, Llc Apoaequorin for reducing neuronal injury due to ischemia
PL2900253T3 (pl) * 2012-09-27 2019-04-30 Quincy Bioscience Llc Kompozycje zawierające apoakworynę, do stosowania w łagodzeniu objawów związanych ze stwardnieniem rozsianym
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
CN109803547A (zh) * 2016-09-23 2019-05-24 昆西生物科学有限公司 含有脱辅基水母素和维生素d的组合物及其使用方法
BR112021016587A2 (pt) 2019-02-22 2021-11-03 Aquero Canada Ltd Composições de leite fortificadas e seus processos de preparação
WO2021173550A1 (en) * 2020-02-24 2021-09-02 Quincy Bioscience, Llc Apoaequorin and curcumin containing compositions and methods
CN116157114A (zh) * 2020-08-20 2023-05-23 昆西生物科学有限公司 含脱辅基水母蛋白的泡腾制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6447379A (en) * 1987-08-19 1989-02-21 Chisso Corp Preparation of calcium-dependent oxygenation enzyme
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
CN1324045C (zh) 2004-09-22 2007-07-04 中国科学院海洋研究所 从水母中分离的具有抗氧化活性的蛋白及其应用

Also Published As

Publication number Publication date
CY1114366T1 (el) 2016-08-31
SI2262525T1 (sl) 2013-03-29
AU2009223010A1 (en) 2009-09-17
US20110124562A1 (en) 2011-05-26
BRPI0909435A2 (pt) 2017-06-13
ES2401754T3 (es) 2013-04-24
DK2262525T3 (da) 2013-02-11
IL207827A (en) 2013-08-29
JP2011513496A (ja) 2011-04-28
PT2262525E (pt) 2013-01-28
CN106692945A (zh) 2017-05-24
CA2717322C (en) 2017-07-11
IL207827A0 (en) 2010-12-30
CA2717322A1 (en) 2009-09-17
EP2262525A1 (en) 2010-12-22
AU2009223010B2 (en) 2014-01-09
NZ588437A (en) 2012-07-27
PL2262525T3 (pl) 2013-04-30
US8796213B2 (en) 2014-08-05
CN101969979A (zh) 2011-02-09
KR20100136494A (ko) 2010-12-28
HRP20130205T1 (hr) 2013-04-30
KR101643662B1 (ko) 2016-07-29
JP5508294B2 (ja) 2014-05-28
WO2009114597A1 (en) 2009-09-17
EP2262525B1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MX2011007930A (es) Conjugados de insulina cristalina.
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
UA109112C2 (uk) Короткотривала високотемпературна обробка, що дозволяє одержати мікробні препарати із протизапальними профілями
MX2010009753A (es) Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2010007490A (es) Preparacion de derivados de sulfamida.
IN2012DN00908A (es)
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
UA99839C2 (ru) Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MY150600A (en) Use of opioid antagonists for treating urinary retention
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
EA201201623A1 (ru) Лечение диабета 2 типа
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MY150931A (en) Substituted oxazolidinones and their use
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
MX2010004814A (es) Metodos para tratar esclerodermia.
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MY157007A (en) Novel possibility of controlling giardiosis
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.

Legal Events

Date Code Title Description
FG Grant or registration